NEW YORK, April 30 - George Poste has been appointed director of Arizona State University's Arizona Biodesign Institute, the university said Tuesday.
Poste is currently Chairman of Orchid Biosciences' board of directors, and chief executive of the consulting group Health Technology Networks, based in
At the Biodesign Institute, Poste will seek to draw a core of researchers to build on its mission of combining biotechnology, nanotechnology, and information technology to improve human health, the university said. He will also spearhead collaborations with industry.
"It's my goal that AzBio will pioneer new approaches in both research and teaching," said Poste, in a statement. "By forging an extensive network of alliances, both on-and off-campus, AzBio will become a dynamic intellectual and economic resource for ASU, the state and the nation."
ASU broke ground on an 170,000 square-foot research facility for the Biodesign Institute in
Robert Weist has resigned from the board of BioSource International, the company said Tuesday.
Weist, who had been a board member of the life sciences reagent system company since 1996, left for "personal reasons," and his resignation is effective immediately. John Zabrieski will replace Weist on the company's audit committee. Also, the company passed a resolution to reduce its board from seven to six members.
Weist has been president of Weist Associates, a management consulting firm, since 1992. He served as president of Hyseq (now Nuvelo) from May 1993 until March 1994, and as chairman of the board of Hyseq from March 1994 until February 2000, according to a Hyseq website. Weist has also previously served as senior vice president, general counsel, and secretary of Amgen from May 1982 until January 1986.
Bill Madia is planning to leave his post as director of Oak Ridge National Laboratory and president of UT-Battelle, to become manager of Battelle's Department of Energy business at its
Madia has served as director of ORNL since April 2000, when Battelle and the
Madia will now manage Battelle's
Michael Dunn has been hired to fill the newly-created position of chief business officer at Aclara Biosciences, and John Mendlein, CEO of Affinium Pharmaceuticals, has been appointed to the company's board of directors, the company said April 28.
Dunn, who will be responsible for business development, sales, and marketing.
comes to Aclara from ActivX Biosciences, where he was vice president of business development.
He previously served as executive VP of business development at Aurora Biosciences.
Mendlein is also an
Simon Mercer has joined GeneCodes as director of software engineering, the company said April 24.
Mercer will report directly to CEO Howard Cash, and will be in charge of allocating programming resources and projects for the company, as well as managing ongoing projects such as the programs Sequencher and M-FISys.
Mercer has been working with GeneCodes since the company took on the challenge of building an informatics tool for forensic work in the wake of the
Professors Raymond Dwek, Max Burger, and Donald Drakeman have all resigned from the Board of Oxford Glycosciences, the company said last week, in the wake of its acquisition by Celltech.
The company has appointed Peter Allen, John Slater, Peter Nicholls, Ian Nicholson, Jonathan Glenn, and Andrew Weir to the Board as non-executive directors, effective from April 17th.